Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
solasia.co.jp

See what CB Insights has to offer

Competitors

14

Business Relationships

7

Service Providers

10

Solasia Pharma Competitors & Alternatives

14 Competitors

Solasia Pharma has 14 competitors. Solasia Pharma's competitors are Ology Bioservices, Adastra Pharmaceuticals, Salix Pharmaceuticals, ANI Pharmaceuticals, Supernus Pharmaceuticals and more.

Latest Funding

Companies

Investment Stage

Total Funding

Mosaic
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

Location

4/12/2021

Acquired

$68.3M

Florida

11/1/2019

Series E - II

$90.65M

New Jersey

4/1/2015

Acq - P2P

New Jersey

6/22/2013

Acq - P2P

$8.7M

Minnesota

5/1/2012

IPO

$60M

Maryland

3/27/2012

ISTA Pharmaceuticals

Acq - P2P

$67.1M

California

8/13/2010

Trubion Pharmaceuticals

Acq - P2P

$45.75M

Washington

1/21/2008

Endotis Pharma

Series B

$36.5M

France

11/14/2007

Qualitest Pharmaceuticals

Acquired

Alabama

6/20/2006

IVREA Pharmaceuticals

Unattributed VC - II

$16.1M

Massachusetts

Latest Funding

4/12/2021

11/1/2019

4/1/2015

6/22/2013

5/1/2012

3/27/2012

8/13/2010

1/21/2008

11/14/2007

6/20/2006

Companies

ISTA Pharmaceuticals

Trubion Pharmaceuticals

Endotis Pharma

Qualitest Pharmaceuticals

IVREA Pharmaceuticals

Investment Stage

Acquired

Series E - II

Acq - P2P

Acq - P2P

IPO

Acq - P2P

Acq - P2P

Series B

Acquired

Unattributed VC - II

Total Funding

$68.3M

$90.65M

$8.7M

$60M

$67.1M

$45.75M

$36.5M

$16.1M

Mosaic

Location

Florida

New Jersey

New Jersey

Minnesota

Maryland

California

Washington

France

Alabama

Massachusetts

Solasia Pharma Service Providers

10 Service Providers

Solasia Pharma has 10 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Investment Bank

Bookrunner

Kyokuto Securities

Investment Bank

Bookrunner

Investment Bank

Bookrunner

Service Provider

Kyokuto Securities

Associated Rounds

Provider Type

Investment Bank

Investment Bank

Investment Bank

Service Type

Bookrunner

Bookrunner

Bookrunner

Partnership data by VentureSource

Solasia Pharma Partners & Customers

7 Partners and customers

Solasia Pharma has 7 strategic partners and customers. Solasia Pharma recently partnered with Nippon Kayaku on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/26/2021

Licensee

Nippon Kayaku

Japan

Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)

TOKYO -- Solasia -LRB- TOKYO : 4597 , Headquarters : Tokyo , Japan , President & CEO : Yoshihiro Arai , hereinafter `` Solasia '' -RRB- and Nippon Kayaku -LRB- TOKYO : 4272 , Headquarters : Tokyo , Japan , President : Atsuhiro Wakumoto -RRB- today jointly announced the conclusion of a license agreement for marketing rights to darinaparsin -LRB- generic name , development code : SP-02 -RRB- in Japan -LRB- hereinafter `` this agreement '' -RRB- .

2

12/10/2019

Licensee

Maruho

Japan

Subscribe to see more

Subscribe to see more

10

11/20/2017

Licensor

PledPharma

Sweden

Subscribe to see more

Subscribe to see more

10

11/9/2017

Vendor

Alcami

United States

Subscribe to see more

Subscribe to see more

10

12/5/2016

Partner

Meiji Seika

Japan

Subscribe to see more

Subscribe to see more

10

Date

10/26/2021

12/10/2019

11/20/2017

11/9/2017

12/5/2016

Type

Licensee

Licensee

Licensor

Vendor

Partner

Business Partner

Nippon Kayaku

Maruho

PledPharma

Alcami

Meiji Seika

Country

Japan

Japan

Sweden

United States

Japan

News Snippet

Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)

TOKYO -- Solasia -LRB- TOKYO : 4597 , Headquarters : Tokyo , Japan , President & CEO : Yoshihiro Arai , hereinafter `` Solasia '' -RRB- and Nippon Kayaku -LRB- TOKYO : 4272 , Headquarters : Tokyo , Japan , President : Atsuhiro Wakumoto -RRB- today jointly announced the conclusion of a license agreement for marketing rights to darinaparsin -LRB- generic name , development code : SP-02 -RRB- in Japan -LRB- hereinafter `` this agreement '' -RRB- .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.